Insmed INSM
NASDAQ INSM
$126.29 -0.39 (-0.31%)
At close: Sep 4, 2026 · 4:00 PM EDT

Insmed (INSM) Income towards Parent Company (2010 - 2026)

Insmed (INSM) posted Income towards Parent Company of -$13.3 million for Q2 2026, up 91.89% on a QoQ basis from -$163.6 million in Q1 2026, and up 95.87% year-over-year from -$6.8 million in Q2 2025.

Analysis

Insmed (INSM) Income towards Parent Company (2010 - 2026) Analysis & Trends

Insmed has reported Income towards Parent Company for 17 years, with the latest figure at -$13.3 million in Q2 2026.

  • On a quarterly basis, Income towards Parent Company rose 95.87% year-over-year to -$13.3 million in Q2 2026; TTM through Jun 2026 was -$875.4 million, a 15.37% increase from a year earlier, with the FY2025 full-year figure at -$1.3 billion, down 39.73% from the prior year.
  • Income towards Parent Company was -$13.3 million for Q2 2026 at Insmed, up from -$163.6 million in the prior quarter.
  • The five-year high for Income towards Parent Company was -$13.3 million in Q2 2026, with the low at -$370.0 million in Q3 2025.
  • Average Income towards Parent Company over 5 years is -$199.9 million, with a median of -$174.8 million recorded in 2023.
  • The sharpest annual moves came in 2023 and 2026: Income towards Parent Company plunged 155.96% in 2023, then soared 95.87% in 2026.
  • Over 5 years, Income towards Parent Company stood at -$160.1 million in 2022, then retreated by 16.22% to -$186.1 million in 2023, then decreased by 26.6% to -$235.5 million in 2024, then plunged by 39.45% to -$328.5 million in 2025, then soared by 95.96% to -$13.3 million in 2026.
  • The last three Income towards Parent Company figures came in at -$13.3 million (Q2 2026), -$163.6 million (Q1 2026), and -$328.5 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.27 Mn
Mar 31, 2026 -163.60 Mn
Dec 31, 2025 -328.46 Mn
Sep 30, 2025 -370.02 Mn
Jun 30, 2025 -321.69 Mn
Mar 31, 2025 -256.58 Mn
Dec 31, 2024 -235.55 Mn
Sep 30, 2024 -220.52 Mn
Jun 30, 2024 -300.61 Mn
Mar 31, 2024 -157.10 Mn
Dec 31, 2023 -186.06 Mn
Sep 30, 2023 -158.93 Mn
Jun 30, 2023 -244.81 Mn
Mar 31, 2023 -159.78 Mn
Dec 31, 2022 -160.10 Mn
Sep 30, 2022 -131.17 Mn
Jun 30, 2022 -95.65 Mn
Mar 31, 2022 -94.64 Mn
Dec 31, 2021 -112.94 Mn
Sep 30, 2021 -112.69 Mn